A recent study detailed how drug decriminalization did not increase the risk of overdose-related deaths.
Conducted by Oregon and Washington, a recent study showed how drug decriminalization was not an instigator in overdose-related deaths (1). Drug policy reform has become a hot topic throughout the US. States such as Washington and Oregon have either fully or partially decriminalized drug possession. The study looked at an overview on overdose-related deaths, one-year post-implementation. Results showed that previous thoughts that the two may be connected were proven wrong.
In February 2021, Oregon enacted Measure 110. This showed that the state was suffering from a significant drug problem and that the state needed to expand access for drug treatment (2). Washington also experienced a State Supreme Court decision with the State v. Blake which stated that their felony drug possession law was considered unconstitutional (3).
MyCannabis mentioned that the study detailed (1):
Through the study’s findings, it shows the impact drug decriminalization can have on public health, as well as the need for further discussion on drug policy reform. An important note to take on this research is to remember that the data was only reviewing the short-term effects of decriminalization and that further investigation into the medium- and long-term effects needs to be explored. Drug reform advocates (1) are hopeful that research such as the study from Oregon and Washington, will bring about new data and legislation which will benefit those incarcerated, as well as public health.
References
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
Assessing Cannabis as a Harm Reduction Strategy: Insights from a Large-Scale Study
November 19th 2024A New Zealand study aimed to assess cannabis use as a harm reduction tool. Findings highlight lifestyle factors, and suggest cannabis-focused harm reduction strategies in reducing other substance use such as alcohol.
Ep 23, Part III: Accreditation in the Cannabis Industry with Susan Audino
October 24th 2024In Part III of this episode, host Evan Friedmann is joined by Susan Audino, PhD, founder of S.A. Audino & Associates, LLC, and co-founder of Saturn Scientific, LLC, to examine the complexities of sampling in the cannabis industry, emphasizing the need for proper sampling plans, and methods.
2 Commerce Drive
Cranbury, NJ 08512